Limits...
Hepatitis B surface antigen levels at 6 months after treatment can predict the efficacy of lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B.

Kim JH, Moon HW, Ko SY, Choe WH, Kwon SY - Clin Mol Hepatol (2014)

Bottom Line: HBsAg levels were not different significantly at baseline (4.0 vs. 3.6 Log10 IU/mL, P=0.072).However, the HBsAg level decreased after 6 months of treatment in patients with a VR and became different significantly between the groups thereafter (3.9 vs. 3.3 at 6 months, P=0.002; 3.8 vs. 3.2 at 1 year, P=0.004; 3.9 vs. 3.2 at 2 years, P=0.008; 3.7 vs. 3.1 at 3 years, P =0.020).The HBsAg level at 6 months after treatment can help predict treatment response.

View Article: PubMed Central - PubMed

Affiliation: Department of Internal Medicine, Konkuk University School of Medicine, Seoul, Korea.

ABSTRACT

Background/aims: Quantitation of hepatitis B surface antigen (HBsAg) is an increasingly popular method to determine the treatment response in chronic hepatitis B (CHB) patients. The clinical value of HBsAg level measurement during rescue therapy for lamivudine (LMV)-resistant CHB patients have not been evaluated to date. Therefore, this study investigated the correlation between HBsAg level and treatment response in LMV-resistant CHB patients treated with adefovir (ADV) add-on therapy.

Methods: LMV-resistant CHB patients treated with LMV-ADV combination therapy for over 2 years were included. HBsAg levels were measured at 6 month intervals until 1 year, and annually thereafter. Treatment response was assessed by determining the virological response (VR, undetectable HBV DNA levels) during treatment.

Results: Fifty patients were included, of which 40 showed a VR. HBsAg levels were not different significantly at baseline (4.0 vs. 3.6 Log10 IU/mL, P=0.072). However, the HBsAg level decreased after 6 months of treatment in patients with a VR and became different significantly between the groups thereafter (3.9 vs. 3.3 at 6 months, P=0.002; 3.8 vs. 3.2 at 1 year, P=0.004; 3.9 vs. 3.2 at 2 years, P=0.008; 3.7 vs. 3.1 at 3 years, P =0.020).

Conclusions: The HBsAg level at 6 months after treatment can help predict treatment response.

Show MeSH

Related in: MedlinePlus

Areas under the receiver operating characteristics curve (AUROCs) of HBsAg levels at each time point for virological response.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4197176&req=5

Figure 3: Areas under the receiver operating characteristics curve (AUROCs) of HBsAg levels at each time point for virological response.

Mentions: The AUROCs of HBsAg levels at 6 months, 1 year and 2 years were 0.770, 0.781, and 0.768, respectively (Fig. 3). These values did not significantly differ (Table 4). With a cutoff value of 3.21 Log10 IU/mL for HBsAg at 6 months, the sensitivity and specificity for predicting a VR were estimated to be 45.0% and 100%, respectively, and the Youden index was 0.45. Kaplan-Meier analysis with the log-rank test showed a significance of difference in the VR rate according to this cutoff value (P<0.001, Fig. 4).


Hepatitis B surface antigen levels at 6 months after treatment can predict the efficacy of lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B.

Kim JH, Moon HW, Ko SY, Choe WH, Kwon SY - Clin Mol Hepatol (2014)

Areas under the receiver operating characteristics curve (AUROCs) of HBsAg levels at each time point for virological response.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4197176&req=5

Figure 3: Areas under the receiver operating characteristics curve (AUROCs) of HBsAg levels at each time point for virological response.
Mentions: The AUROCs of HBsAg levels at 6 months, 1 year and 2 years were 0.770, 0.781, and 0.768, respectively (Fig. 3). These values did not significantly differ (Table 4). With a cutoff value of 3.21 Log10 IU/mL for HBsAg at 6 months, the sensitivity and specificity for predicting a VR were estimated to be 45.0% and 100%, respectively, and the Youden index was 0.45. Kaplan-Meier analysis with the log-rank test showed a significance of difference in the VR rate according to this cutoff value (P<0.001, Fig. 4).

Bottom Line: HBsAg levels were not different significantly at baseline (4.0 vs. 3.6 Log10 IU/mL, P=0.072).However, the HBsAg level decreased after 6 months of treatment in patients with a VR and became different significantly between the groups thereafter (3.9 vs. 3.3 at 6 months, P=0.002; 3.8 vs. 3.2 at 1 year, P=0.004; 3.9 vs. 3.2 at 2 years, P=0.008; 3.7 vs. 3.1 at 3 years, P =0.020).The HBsAg level at 6 months after treatment can help predict treatment response.

View Article: PubMed Central - PubMed

Affiliation: Department of Internal Medicine, Konkuk University School of Medicine, Seoul, Korea.

ABSTRACT

Background/aims: Quantitation of hepatitis B surface antigen (HBsAg) is an increasingly popular method to determine the treatment response in chronic hepatitis B (CHB) patients. The clinical value of HBsAg level measurement during rescue therapy for lamivudine (LMV)-resistant CHB patients have not been evaluated to date. Therefore, this study investigated the correlation between HBsAg level and treatment response in LMV-resistant CHB patients treated with adefovir (ADV) add-on therapy.

Methods: LMV-resistant CHB patients treated with LMV-ADV combination therapy for over 2 years were included. HBsAg levels were measured at 6 month intervals until 1 year, and annually thereafter. Treatment response was assessed by determining the virological response (VR, undetectable HBV DNA levels) during treatment.

Results: Fifty patients were included, of which 40 showed a VR. HBsAg levels were not different significantly at baseline (4.0 vs. 3.6 Log10 IU/mL, P=0.072). However, the HBsAg level decreased after 6 months of treatment in patients with a VR and became different significantly between the groups thereafter (3.9 vs. 3.3 at 6 months, P=0.002; 3.8 vs. 3.2 at 1 year, P=0.004; 3.9 vs. 3.2 at 2 years, P=0.008; 3.7 vs. 3.1 at 3 years, P =0.020).

Conclusions: The HBsAg level at 6 months after treatment can help predict treatment response.

Show MeSH
Related in: MedlinePlus